Metformin reduced cardiovascular mortality in overweight type 2 diabetics (UKPDS). Growing evidence for anti-inflammatory and anti-atherosclerotic effects via AMPK activation has sparked interest in repurposing metformin for cardiovascular prevention in non-diabetics.
Research summaries are AI-generated from open-access peer-reviewed literature (PubMed Central, Cochrane, AHA/ACC). Content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.